This session gives an introductory overview of all the steps required to design, set up and complete an academic cancer trial conducted in the hospital setting.

Participants will know what all the organisations and people involved in trials do and what permissions and documents need to be in place at different stages of a trial. The course is of most interest to those new to working in academic cancer clinical trials.  Those currently working in the field who would like to gain an overview of what happens at other stages to the one familiar to them, may also benefit.

This course runs from 10.00 - 13.00

This session is a basic introduction to cancer treatments and their most common side effects and adverse reactions. The course provides an overview on cancer surgery, radiotherapy and chemotherapy we well as insights on the mechanisms of action of targeted therapies such as monoclonal antibodies, small inhibitory molecules, CAR-T cell therapy and immune checkpoint inhibitors.

In the second part of the session, participants will learn about the mechanisms of toxicity linked to the different categories of cancer therapy and how these are managed.

This course is not recommended for clinicians.

Please note that this course runs from 10.00-13.00

This session, aimed at non-statisticians, will cover the most common primary outcomes measures used in early and late phase cancer trials.

Learning Outcomes:

Participants will learn what makes a good outcome measure, how outcomes measures are defined and what data need to be collected to assess the outcome, especially for tumour response assessment and time to event measures such as survival and disease (or progression) free survival.

Please note that this course runs from 10.00-13.00

This is a newly developed training session that covers the following aspects:

• Introduction to response assessment criteria: why do we need standards
• RECIST criteria guidelines: how are these reflected in the Trial Protocol?
• RECIST and iRECIST: what are the differences?
• Imaging methods of response assessment
• Design and analysis of trials using response assessment
• Response assessment in the future generation of cancer trials

The course will dedicate ample time to the development of practical skills to learn how to evaluate response according to both RECIST 1.1 and iRECIST via the following activities:

• Calculation tables to evaluate response
• Real life CRFs review in groups
• Case study discussion
• Quizzes

Please note that this course runs from 09.30-13.00

This session gives a comprehensive overview of the clinical pathways cancer patients can take to be eventually referred for trial entry. The first part of the session spans across the diagnostic methods and staging of cancer and gives a brief overview of the common tests carried out prior to trial treatment.

In the second part of the session participants will learn about the importance of ensuring only eligible patients enter a trial and how eligibility criteria help to safeguard patients and differ amongst different phases of trials. They will also learn the importance of assessing treatment compliance and how every clinical intervention comes with a different set of challenges in collecting data about patient compliance.

Please note this course runs from 10.00-13.00

This two-day introductory course is aimed at recent MSc graduates or experienced statisticians new to the field of cancer trials. The course outlines how cancer forms, is diagnosed, staged and treated and links this information to the main outcome measures reported on in cancer clinical trials. By attending this course participants will be better placed to produce cancer clinical trial reports for Data-Monitoring Committees or publications. The faculty of experienced statistical, trial and clinical staff are from three UKCRC Accredited Clinical Trial Units.